Epitope-based vaccines: an update on epitope identification, vaccine design and delivery.
The basic premise of the epitope-based approach to vaccine development is that, in certain cases, the responses induced by the natural immunogen are not optimal, and can be improved upon by isolation or optimization of specific components of the response. For example, immunodominance is a key factor limiting the type and breadth of adaptive immunity. Recent advances in understanding the mechanisms of immunodominance thus represent an opportunity to further develop the epitope-based approach.
Sette
Alessandro
A
La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA. alex@liai.org
Fikes
John
J
D019496:Cancer Vaccines / Q000276:immunology; D002986:Clinical Trials as Topic; D000939:Epitopes / Q000008:administration & dosage / Q000276:immunology*; D005802:Genes, MHC Class II / Q000276:immunology; D006801:Humans; D016056:Immunodominant Epitopes / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*
D019496:Cancer Vaccines; D000939:Epitopes; D016056:Immunodominant Epitopes; D014612:Vaccines